We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Newsmaker: Anaphore.
- Authors
Rohn, Jennifer
- Abstract
The article features Anaphore, the La Jolla, California-based protein engineering firm which was able to launch a new class of protein pharmaceuticals called atrimers despite a challenging economy. The funds used for the products came from the 38 million U.S. dollars raised by the firm in a series A round from its investors, including Apposite Capital and Merck Serono Ventures. It is noted that autoimmune diseases and cancer are the main targets of Anaphore.
- Subjects
ANAPHORE Inc.; PROTEIN drugs; INVESTORS; MERCK Serono SA; APPOSITE Capital (Company); AUTOIMMUNE diseases; PROTEIN engineering
- Publication
Nature Biotechnology, 2010, Vol 28, Issue 11, p1143
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt1110-1143